Gene Therapy Ameliorates Cardiovascular Disease in Dogs With Mucopolysaccharidosis VII

M.M. Sleeper, VMD; B. Fornasari, DVM; N.M. Ellinwood, DVM, PhD; M.A. Weil, AS; J. Melniczek, VMD; T.M. O’Malley, BS; C.D. Sammarco, BVSc, MRCVS; L. Xu, MD; K.P. Ponder, MD; M.E. Haskins, VMD, PhD

Background—Mucopolysaccharidosis VII (MPS VII) is a lysosomal storage disease caused by deficient β-glucuronidase (GUSB) activity resulting in defective catabolism of glycosaminoglycans (GAGs). Cardiac disease is a major cause of death in MPS VII because of accumulation of GAGs in cardiovascular cells. Manifestations include cardiomyopathy, mitral and aortic valve thickening, and aortic root dilation and may cause death in the early months of life or may be compatible with a fairly normal lifespan. We previously reported that neonatal administration of a retroviral vector (RV) resulted in transduction of hepatocytes, which secreted GUSB into the blood and could be taken up by cells throughout the body. The goal of this study was to evaluate the effect on cardiac disease.

Methods and Results—Six MPS VII dogs were treated intravenously with an RV-expressing canine GUSB. Echocardiographic parameters, cardiovascular lesions, and biochemical parameters of these dogs were compared with those of normal and untreated MPS VII dogs.

Conclusions—RV-treated dogs were markedly improved compared with untreated MPS VII dogs. Most RV-treated MPS VII dogs had mild or moderate mitral regurgitation at 4 to 5 months after birth, which improved or disappeared when evaluated at 9 to 11 and at 24 months. Similarly, mitral valve thickening present early in some animals disappeared over time, whereas aortic dilation and aortic valve thickening were absent at all times. Both myocardium and aorta had significant levels of GUSB and reduction in GAGs.

Key Words: cardiovascular diseases • gene therapy • lysosomes • mucopolysaccharidosis
in research. Six MPS VII dogs (M1287, M1312, M1328, M1332, M1337, and M1339) had 20 mL of an RV containing the normal canine GUSB cDNA injected intravenously at 2 to 3 days of age as described previously. One dog (M1287) was pretreated with human hepatocyte growth factor (HGF) before injection of RV.

Echocardiography

MPS VII–treated dogs were evaluated by physical examination and echocardiography with a Hewlett Packard 5500 Sonos ultrasound machine. All dogs were restrained in right and left lateral recumbency, with imaging performed from below by use of a cut-out table. The same, blinded sonographer (board-certified veterinary cardiologist) performed and scored all echocardiograms, 2D and M-mode echocardiography was performed with a 7.5- or 5-MHz probe. All valves were interrogated with color flow Doppler and pulse-wave Doppler using a 3.5-mHz transducer. A subjective score was assigned for mitral and aortic valve thickening, aortic root diameter (taken from the short-axis view at the level of the sinuses of Valsalva and at the level of the sinotubular junction from a long-axis plane), and quantity of valvular regurgitation. Results were evaluated by paired t test analysis.

Pathology

Euthanasia of dog M1312 was at 6 months of age with 80 mg/kg of sodium pentobarbital (Veterinary Laboratories, Inc). Dog M1339 died at 7 months of age while under propofol anesthesia. He appeared to be in good health before the procedure. The dogs were perfused with 2 L of cold saline before the collection of tissues, which were frozen immediately on dry ice or placed in buffered 10% sodium cacodylate. Sections of paraffin-embedded aorta and myocardium 6 μm thick were stained with hematoxylin and eosin. Histochemical staining with naphthol-AS-BI-beta-d-glucuronide for GUSB activity was performed on frozen sections as described previously.

β-Glucuronidase and Total Hexosaminidase Assays

GUSB and total hexosaminidase A activities were measured by use of the respective fluorogenic substrates as described previously. Activity was expressed as nanomoles of 4-methylumbelliferone released per hour per milligram protein.

GAG Assays

Total sulfated GAGs were assayed by measurement of Alcian blue on the basis of the principles of Bjornsson and as described previously. Samples were normalized to protein concentrations (Biorad) and reported as micrograms total sulfated GAGs per milligram protein.

Results

We previously reported transduction of hepatocytes from 6 MPS VII dogs with an RV containing a normal copy of the canine GUSB cDNA after intravenous injection into newborns. The dogs had high levels of serum GUSB for 14 months after transfer, which have remained stable for more than 3 years (data not shown). No adverse clinical effects were evident from the time of the last report to the present.

Physical Examination and Echocardiography

Complete physical examinations and echocardiography were performed in untreated MPS VII, RV–treated MPS VII, and normal dogs. At 1 year of age, 3 of 4 untreated MPS VII dogs had murmurs of mitral valve regurgitation (MR), and all 4 dogs had echocardiographic evidence of MR, mitral valve thickening, and aortic root dilation. These results are consistent with our previous evaluation of 13 untreated MPS VII dogs 0.3 to 1.3 years old of which 9 of 13 had murmurs and all had mitral valve thickening, MR, aortic root dilation, and aortic valve thickening. The oldest untreated MPS VII dog evaluated was only 1.3 years old, because MPS VII dogs undergo euthanasia because of the progression of skeletal deformity and an inability to stand or walk beyond 6 months of age. None of the untreated MPS VII dogs had clinical signs consistent with congestive heart failure.

Six RV–treated dogs were evaluated at 4 to 5 months after birth. Three of these dogs were also evaluated by echocardiography at 8 to 9 months and 24 months, and 2 were euthanized at 6 to 7 months. Mitral valves were mildly thickened in 4 (M1312, M1328, M1332, and M1339) of the 6 treated puppies at the time of initial evaluation (4 to 5 months of age). Mitral valve thickening was not detectable at the later times of evaluation (Figure 1). Insignificant MR was present by echocardiography in 2 (M1328 and M1332) of the 4 treated dogs evaluated at 9 to 11 months of age; in all 4, valve thickness was normal, and none of the dogs had murmurs. At 2 years of age, murmurs were still absent, and echocardiography showed normal mitral valve thickness and either minimal (in 1 dog, M1328) or no MR. The mild MR present in M1328 was consistent with the trivial valvular leaks that can often be found in normal dogs with close scrutiny of the valves by use of color flow Doppler. A similar amount of MR was detected in 3 of the 7 control dogs. The Data Supplement Movies demonstrate color flow Doppler echocardiograms at the mitral valve in an MPS VII dog, an RV–treated MPS VII dog, an HGF/RV–treated MPS VII dog, and an unaffected dog. The color flow Doppler jet of MR is present only in the untreated affected individual.

All RV–treated dogs evaluated had normal thickness of the tricuspid, aortic, and pulmonary valves and no aortic valve insufficiency, and the aortic diameter was subjectively within normal limits at all evaluations (Figure 2). Of 7 control dogs without MPS VII (6 to 38 months old), none had ausculatable murmurs on physical examination. However, 3 of the 7 had mild MR with no other abnormalities detected on echocardiography. All valves were subjectively of normal thickness.

β-Glucuronidase and Hexosaminidase Activity

Aortic root and left ventricular free wall GUSB activity was quantified. In 4 untreated MPS VII dogs, the GUSB in the aorta and myocardium was 0±0 U/mg (0% of normal) and 0.50±0.6 U/mg (0.5% of normal), respectively, as shown in Figure 3. In the 2 RV–treated MPS VII dogs, the mean GUSB activity in the aorta and myocardium was 16 U/mg (17.5% of normal) and 6 U/mg (19.3% of normal), respectively.

In many lysosomal storage diseases, levels of other lysosomal enzymes are elevated, and the activity falls to normal levels when lysosomal storage is reduced. The hexosaminidase A activity in untreated MPS VII dogs (Figure 3) was 6174±2686 U/mg (1342% of normal) and 1556±179 U/mg (416% of normal) for the aorta and myocardium, respectively. In the 2 RV–treated dogs, the hexosaminidase A activity was reduced to 1500 U/mg (326% of normal) and 681 U/mg (182% of normal) in the aorta and myocardium, respectively.

GAG Content

Untreated MPS VII dogs had 119±34 μg GAG/mg protein (365% of normal) and 2.5±0.6 μg GAG/mg protein (208%
The average GAG levels in the RV-treated MPS VII dogs were reduced to 67.2 μg/mg protein (178% of normal) and 1.6 μg/mg protein (178% of normal) for aorta and myocardium, respectively.

Pathology

RV-treated MPS VII and control dogs were necropsied at 6 to 7 months of age. In the 2 untreated MPS VII littermates, the mitral valve had nodular thickening 3 to 4 mm in diameter, and the chordae tendineae were thickened (Figure 4B). In contrast, thickening of the mitral valves and chordae tendineae was mild in the RV-treated MPS VII dogs (Figure 4, C and D). Histologically, myocardial lesions in the untreated and RV-treated MPS VII dogs were minimal, with only a few rounded fibroblasts in the perivascular connective tissue with minimal to moderate hypertrophy and moderately vacuolated cytoplasm (data not shown). Histologically, the mitral valve nodules from the MPS VII-affected dogs consisted of loose connective tissue, with most fibroblasts severely hypertrophied with moderate to many cytoplasmic inclusions containing amorphous material, representing lysosomal storage. In 1 dog, subendocardial cells were severely hypertrophic, with highly vacuolated cytoplasm. Histologically, in the RV-treated dogs, mild rounding of perivascular fibroblasts was present with minimal to moderate hypertrophy and cytoplasm with comparatively few large, pale pink vacuoles containing amorphous material.

Grossly, the aortic wall thickness, particularly the media, was increased in the untreated MPS VII dogs. In the RV-treated dogs, the aortic wall thickness was also increased, and in contrast to normal, the lumen was irregular. Histology of the untreated MPS VII dog aortas revealed that the normally fusiform smooth muscle cells of the media were rounded and severely hypertrophic, with highly vacuolated cytoplasm containing amorphous material (lysosomes distended with GAGs) (Figure 5, C and D). Histology of the aorta from the RV-treated dogs revealed that most smooth muscle cells in the media were fusiform and appeared normal, with few cells appearing rounded, with minimal to moderate hypertrophy and vacuolated cytoplasm (Figure 5, E through H).

In the RV-treated dogs, histochemical staining for GUSB activity showed enzyme activity in some cells throughout the entire thickness of the aortic wall, with most staining present in smooth muscle cells of the media (Figure 6C). GUSB activity was apparent in occasional cells in the myocardium (data not shown).
Various MPS syndromes result in cardiovascular abnormalities, which may include valvular thickening, regurgitation and/or stenosis, and aortic dilation. Affected individuals can be treated by providing normal enzyme in 1 of 3 ways: (1) enzyme replacement therapy, (2) BMT, or (3) gene therapy. Enzyme replacement therapy and BMT have both been successful in reducing the cardiac manifestations of MPS in animals and humans. However, enzyme replacement therapy is expensive and requires frequent, lifelong administration, and BMT has traditionally resulted in substantial risks for patients, although recent development of nonablative marrow transplant with high cell dosage has proved to be effective and safer. One child with MPS VII has been studied after BMT therapy at 12 years of age. Mitral and aortic valve regurgitation did not change in the 15 months after therapy, nor did valve abnormalities improve in a group of MPS I, IV, and VI children treated with BMT. The effect on the heart of gene therapy of hematopoietic cells in MPS VII mice was not reported.

The cardiovascular abnormalities seen by echocardiography in untreated MPS VII dogs in this and a previous study included thickening of the mitral valve with MR, large aortic dimensions in the short- and long-axis views, and thickening of the aortic valve. All of the 4 RV-treated MPS VII dogs that were treated with RV shortly after birth (RV-treated MPS VII) were euthanized at 6 to 7 months of age. Aorta and myocardium were collected from 4 normal dogs (Normal), 4 untreated MPS VII (MPS VII Affected), and 2 MPS VII dogs that were treated with RV shortly after birth (RV-treated MPS VII). Samples were homogenized, and GUSB activity, hexosaminidase A activity, and GAG levels were determined and normalized to amount of protein in sample and plotted as average ± SD. Levels for aorta and myocardium are plotted on same scale. Hexosaminidase A is another lysosomal enzyme, levels of which are increased in untreated MPS VII dogs.

Discussion

Various MPS syndromes result in cardiovascular abnormalities, which may include valvular thickening, regurgitation and/or stenosis, and aortic dilation. Affected individuals can be treated by providing normal enzyme in 1 of 3 ways: (1) enzyme replacement therapy, (2) BMT, or (3) gene therapy. Enzyme replacement therapy and BMT have both been successful in reducing the cardiac manifestations of MPS in animals and humans. However, enzyme replacement therapy is expensive and requires frequent, lifelong administration, and BMT has traditionally resulted in substantial risks for patients, although recent development of nonablative marrow transplant with high cell dosage has proved to be effective and safer. One child with MPS VII has been studied after BMT therapy at 12 years of age. Mitral and aortic valve regurgitation did not change in the 15 months after therapy, nor did valve abnormalities improve in a group of MPS I, IV, and VI children treated with BMT. The effect on the heart of gene therapy of hematopoietic cells in MPS VII mice was not reported.

The cardiovascular abnormalities seen by echocardiography in untreated MPS VII dogs in this and a previous study included thickening of the mitral valve with MR, large aortic dimensions in the short- and long-axis views, and thickening of the aortic valve. All of the 4 RV-treated MPS VII dogs that were treated with RV shortly after birth (RV-treated MPS VII) were euthanized at 6 to 7 months of age. Aorta and myocardium were collected from 4 normal dogs (Normal), 4 untreated MPS VII (MPS VII Affected), and 2 MPS VII dogs that were treated with RV shortly after birth (RV-treated MPS VII). Samples were homogenized, and GUSB activity, hexosaminidase A activity, and GAG levels were determined and normalized to amount of protein in sample and plotted as average ± SD. Levels for aorta and myocardium are plotted on same scale. Hexosaminidase A is another lysosomal enzyme, levels of which are increased in untreated MPS VII dogs.
tion is only a few percent of normal.\textsuperscript{19,29} Although the 2 dogs were perfused with saline after death to remove blood containing GUSB, the procedure may have been imperfect, yielding higher tissue levels. Regardless, the amount of GUSB activity was sufficient to reduce the tissue GAG concentration, albeit not to normal levels. The lack of complete normalization of the cardiac GAG content is somewhat paradoxical, because BMT produced a reduction of GAG to normal levels in 3 BMT-treated dogs, although some residual signs of storage persisted on histopathological assessments.\textsuperscript{6}

Optimal therapy aims to normalize cardiovascular structures or at least prevent the progressive anatomic deterioration that is often observed in the MPS syndromes. From the findings in this report, the cardiovascular lesions of MPS VII in dogs were ameliorated with neonatal intravenous RV gene therapy. Valve replacement has been performed successfully in humans with MPS IS,\textsuperscript{30} MPS IIIB,\textsuperscript{31} and MPS IV\textsuperscript{32} when progressive deterioration necessitated therapy to prevent further progression of disease. Alternatively, medical management may control congestive heart failure. RV gene therapy appears to be superior to BMT, because a matched donor and pretransplant conditioning are not necessary. No adverse effects secondary to gene therapy have been detected thus far. However, because most children with lysosomal storage diseases are currently not diagnosed at birth, RV gene therapy will need to be evaluated in older MPS VII dogs to determine whether adequate transduction can be achieved and what minimal level of GUSB is necessary to control the cardiovascular disease.

**Acknowledgments**

This work was supported by National Institutes of Health grants DK-54481, RR-02512, RR-T32-07063, and DK-54061. We would like to acknowledge Patty O’Donnell and Jean Zweigle, veterinary students, and the University Laboratory Animal Resources staff for advice and assistance with the animal colony.


References

Gene Therapy Ameliorates Cardiovascular Disease in Dogs With Mucopolysaccharidosis VII

_Circulation_. 2004;110:815-820; originally published online August 2, 2004;
doi: 10.1161/01.CIR.0000138747.82487.4B
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/110/7/815

Data Supplement (unedited) at:
http://circ.ahajournals.org/content/suppl/2004/08/16/01.CIR.0000138747.82487.4B.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/